{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-262560","form_type":"8-K","ticker":null,"cik":"0001845337","company_name":"Day One Biopharmaceuticals, Inc.","filed_at":"2024-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.007772+00:00","generated_at":"2026-05-29T22:06:46.397891+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Day One Biopharma R&D Head Samuel Blackman retiring; to advise","bullets":["Samuel Blackman, co-founder and Head of R&D, will retire effective end of 2024.","Blackman served as Head of R&D since May 2023; previously Chief Medical Officer since founding.","He will remain as a strategic advisor and consultant during search for successor.","Company has initiated search for new Head of Research & Development."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-262560","json":"https://secwatch.observer/filing/0001193125-24-262560.json","markdown":"https://secwatch.observer/filing/0001193125-24-262560.md","text":"https://secwatch.observer/filing/0001193125-24-262560.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1845337/000119312524262560/0001193125-24-262560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1845337/000119312524262560/d856064d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T22:06:46.397891+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d282008ffc","claim":"Samuel Blackman departed as Head of Research & Development at Day One Biopharmaceuticals, Inc..","evidence_excerpt":"On November 20, 2024, Samuel Blackman, M.D., Ph.D, notified Day One Biopharmaceuticals, Inc. (the “Company”) of his intention to retire from his position as Head of Research & Development of the Company effective at the end of 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845337/000119312524262560/0001193125-24-262560-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retire"},{"label":"Role","value":"Head of Research & Development"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}